Please login to the form below

Not currently logged in
Email:
Password:

Hugh Cole joins Jounce Therapeutics as chief business officer

He also takes up a head of corporate development role at the US firm

Hugh ColeUS clinical-stage pharmaceutical company Jounce Therapeutics has appointed Hugh Cole as its new chief business officer and head of corporate development.

Cole brings over 25 years’ experience in biotech including business development, corporate strategy, R&D, alliance management, commercial planning and execution and corporate leadership.

He has most recently served as chief business officer at Ariad Pharmaceuticals, where he led several business development transactions for the company and helped develop and implement Ariad’s new corporate strategy.

Richard Murray, chief executive officer, Jounce Therapeutics, said: “Hugh has a tremendous experience and a great track record in the pharmaceutical and biotechnology industries, with robust knowledge of oncology pipeline progression and commercial strategy.

“We are thrilled to welcome him to Jounce at a critical point in our drug development process.”

In addition to his former role at Ariad, Cole was former senior vice president, strategic planning and programme management at Shire, where he oversaw the company’s portfolio management and rare disease processes.

He has also held roles for Oscient Pharmaceuticals, The Wilkerson Group and Fred Alger Management.

Murray added: “As we continue with the clinical development of our lead programme, JTX-2011, and progress our pipeline of innovative immunotherapies, it will be crucial to have Hugh’s business, strategic leadership and management expertise.”

24th August 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Numbers, navigation, and narratives: digital storytelling in medical communications
Science and storytelling aren’t often seen as compatible. One is based on cold, hard facts, while the other is synonymous with improvisation and theater. However, when done well, storytelling can...
Is this common data mistake killing your digital patient recruitment?
Without realising, you could be falling into the trap of using social data — insights into recent, relevant trends and topics — to inspire your content. Hold up. That sounds...
Dr Henry Skinner
The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
By Henry Skinner, Chief Executive Officer of the AMR Action Fund...